IKT (STOCKS)
Inhibikase Therapeutics, Inc. Common Stock
$2.410000
+0.010000 (+0.42%)
Prev close: $2.400000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Mark T. Iwicki
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $365.95M
- Employees
- 16
- P/E (TTM)
- -5.50
- P/B (TTM)
- 2.07
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $3.72M |
| Costs And Expenses | $65.44M |
| Selling, General, and Administrative Expenses | $27.42M |
| Research and Development | $38.24M |
| Operating Income/Loss | -$65.44M |
| Income/Loss From Continuing Operations After Tax | -$12.43M |
| Income/Loss From Continuing Operations Before Tax | -$12.05M |
| Income Tax Expense/Benefit | $0.00 |
| Interest Income/Expense After Provision For Losses | $4.80M |
| Interest Income/Expense Operating, Net | $4.80M |
| Net Income/Loss | -$60.64M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$60.64M |
| Net Income/Loss Available To Common Stockholders, Basic | -$60.64M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$0.43 |
| Diluted Earnings Per Share | -$0.43 |
| Basic Average Shares | 445,371,833 |
| Diluted Average Shares | 445,371,833 |
| Assets | $163.59M |
| Current Assets | $162.34M |
| Prepaid Expenses | $2.35M |
| Other Current Assets | $160.00M |
| Noncurrent Assets | $1.24M |
| Non-current Prepaid Expenses | $1.00M |
| Other Non-current Assets | $244.70K |
| Liabilities | $10.26M |
| Current Liabilities | $10.26M |
| Accounts Payable | $991.72K |
| Other Current Liabilities | $9.27M |
| Noncurrent Liabilities | $0.00 |
| Equity | $153.33M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $153.33M |
| Liabilities And Equity | $163.59M |
| Net Cash Flow From Operating Activities | -$42.61M |
| Net Cash Flow From Operating Activities, Continuing | -$42.61M |
| Net Cash Flow From Investing Activities | -$115.24M |
| Net Cash Flow From Investing Activities, Continuing | -$115.24M |
| Net Cash Flow From Financing Activities | $111.31M |
| Net Cash Flow From Financing Activities, Continuing | $111.31M |
| Net Cash Flow | -$46.54M |
| Net Cash Flow, Continuing | -$46.54M |
| Other Comprehensive Income/Loss | -$60.71M |